Clinical Trial Update: Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing the long-term impact of rapid intravenous infusion of velaglucerase alfa (VPRIV) for Gaucher disease type 1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• Velaglucerase alfa (velaglucerase alfa)

Snippet

Sponsor: Shaare Zedek Medical Center | Conditions: Gaucher Disease, Type 1 | Phase 4 | Status: COMPLETED